NCT07193511 2026-04-16
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
292 trialsNCT06803680 2026-04-15
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT04799054 2026-04-13
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma A/S
Phase 1/2 Terminated
NCT04802759 2026-04-13
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT07335497 2026-04-13
ASCEND
Crescent Biopharma, Inc.
Phase 1/2 Recruiting
NCT07524140 2026-04-13
Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts.
Eilean Therapeutics
Phase 1 Not yet recruiting
NCT05261399 2026-04-06
SAFFRON
AstraZeneca
Phase 3 Active not recruiting
NCT07455617 2026-04-06
Study of ABO2102 in KRAS-Mutated Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1 Recruiting
NCT04050709 2026-04-01
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
ImmunityBio, Inc.
Phase 1 Completed
NCT07213817 2026-04-01
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT07213830 2026-03-31
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Ipsen
Phase 1/2 Recruiting
NCT04639219 2026-03-23
DPT01
AstraZeneca
Phase 2 Active not recruiting
NCT04419532 2026-03-20
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Phase 1 Active not recruiting
NCT05720117 2026-03-20
A Study of PYX-201 in Advanced Solid Tumors
Pyxis Oncology, Inc
Phase 1 Recruiting
NCT07403721 2026-03-19
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Amgen
Phase 1 Recruiting
NCT04443088 2026-03-18
KEYNOTE-E12
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1 Recruiting
NCT05719558 2026-03-18
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT06540066 2026-03-16
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT07030712 2026-03-16
MK-8294-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT05935098 2026-03-13
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT05557045 2026-03-12
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT06713369 2026-03-04
AZD5305
AstraZeneca
Phase 1 Recruiting
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT06521554 2026-02-25
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Nuvalent Inc.
Phase 1 Recruiting
NCT00750841 2026-02-23
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
NCT06005974 2026-02-23
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
Recursion Pharmaceuticals Inc.
Phase 2 Terminated
NCT05396833 2026-02-19
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
EMD Serono
Phase 1 Active not recruiting
NCT07143045 2026-02-09
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.
Recruiting
NCT06127407 2026-02-06
CHONQUER
Servier
Phase 3 Recruiting
NCT03964727 2026-01-30
TROPiCS-03
Gilead Sciences
Phase 2 Active not recruiting
NCT04170153 2026-01-30
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
EMD Serono
Phase 1 Active not recruiting
NCT03697304 2026-01-27
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Boehringer Ingelheim
Phase 2 Completed
NCT05914545 2026-01-22
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04471987 2026-01-14
DODEKA
Philogen S.p.A.
Phase 1 Recruiting
NCT05875168 2026-01-12
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Daiichi Sankyo
Phase 1/2 Recruiting
NCT06235437 2026-01-07
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141
Ascendo Biotechnology Co., Ltd.
Phase 1 Recruiting
NCT04648254 2025-12-30
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
Qurient Co., Ltd.
Phase 1 Completed
NCT06952010 2025-12-26
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Exelixis
Phase 1 Recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT05270213 2025-12-19
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Riboscience, LLC.
Phase 1 Recruiting
NCT05731271 2025-12-17
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1/2 Active not recruiting
NCT05165433 2025-12-16
FORTIFY
Akamis Bio
Phase 1 Completed
NCT06108050 2025-12-16
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT04009681 2025-12-15
HAMMER
Synthorx, Inc, a Sanofi company
Phase 1/2 Terminated
NCT04898543 2025-12-11
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
ImmunityBio, Inc.
Phase 1 Active not recruiting
NCT06724042 2025-12-10
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1 Not yet recruiting
NCT07021898 2025-12-03
BOREALIS-1
Erasca, Inc.
Phase 1 Recruiting
NCT05586321 2025-11-24
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
Genmab
Phase 1 Completed
NCT04214288 2025-11-20
SERENA-2
AstraZeneca
Phase 2 Active not recruiting